Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
Roche launches new highly-sensitive test to more easily diagnose patients who may have B-cell lymphoma
01:00am, Thursday, 20'th Jun 2024
Basel, 20 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the launch of the first clinically approved, highly-sensitive in-situ hybridisation (ISH) test, the VENTANA® Kappa and Lambda
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
02:31pm, Wednesday, 19'th Jun 2024
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
07:15am, Wednesday, 19'th Jun 2024
The Alzheimer's treatment landscape presents a compelling opportunity for investors in healthcare and biotech. Alzheimer's disease is a progressive and debilitating neurodegenerative disorder that pos
More Of The Same Isn't Good Enough For Roche
04:03pm, Tuesday, 18'th Jun 2024
Roche continues to face challenges tied to lackluster revenue and profit outlook, questionable pipeline, and an underperforming diagnostics business. Roche spends aggressively on its pipeline (R&D and
Roche receives FDA clearance on its digital pathology solution for diagnostic use
01:00am, Tuesday, 18'th Jun 2024
The solution, which includes the VENTANA DP 200 slide scanner, Roche's digital pathology workflow software and a display, is now cleared to aid in clinical diagnosis, enabling pathologists to diagnose
Roche (RHHBY) Reports Upbeat Data on Columvi From STARGLO Study
11:20am, Monday, 17'th Jun 2024
Roche's (RHHBY) Columvi significantly extends survival in patients with relapsed or refractory diffuse large B-cell lymphoma in the phase III STARGLO study.
Veteran investor David Roche 'optimistic' U.S. rate cuts are coming
07:30am, Monday, 17'th Jun 2024
David Roche, president and global strategist at Independent Strategy, weighs in on the outlook for U.S. interest rates, saying he is "optimistic" that cuts are coming.
LIXTE Biotechnology Holdings to Collaborate with Roche and Netherlands Cancer Institute in New Colon Cancer Clinical Trial
09:30am, Friday, 14'th Jun 2024
Clinical trial to test recent findings that show LIXTE's lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system
Roche (RHHBY) NSCLC Drug Alecensa Gets EC Nod for Label Expansion
01:01pm, Monday, 10'th Jun 2024
Roche's (RHHBY) Alecensa gets the European Commission's approval as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer.
Roche Diagnostics Company Profile 2024, Featuring a Detailed Product Pipeline Analysis and Ongoing Clinical Trials Insights
07:44am, Monday, 10'th Jun 2024
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Roche Diagnostics International Ltd - Product Pipeline Analysis, 2024 Update" company profile has been added to ResearchAndMarkets.com's offering. This r
Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization
01:05am, Monday, 10'th Jun 2024
Basel, 10 June 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its cobas® liat SARS-CoV-
European Commission approves Roche's Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new 5-year data confirming the sustained efficacy and safety profile
Basel, 07 June 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new five-year data confirming the sustained efficacy and safety profile of Evrysdi® (risdiplam) in children with Type 1 spinal
Roche's head of cardiovascular disease dissects GLP-1 drug trial results
06:16pm, Wednesday, 05'th Jun 2024
Manu Chakravarthy, Roche SVP & global head of cardiovascular disease, joins 'Fast Money' to talk the company's recent weight-loss drug trial results.
